ArticleTherapeutic advances in medical oncology2023

Phase Ib study of HSP90 inhibitor, onalespib (AT13387), in combination with paclitaxel in patients with advanced triple-negative breast cancer.

Nicole O Williams et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.